Blood Test Using P-Tau217 Biomarker Can Predict Alzheimer's Risk Years Before Symptoms Appear, Study Finds

Jul 15, 2026

A major international study of 2,684 healthy older adults reveals that a blood test for the p-tau217 biomarker can predict Alzheimer's risk years before symptoms appear. Individuals with very high baseline levels face a 38% risk of cognitive impairment within 5 years and a 78% risk within 10 years. While the FDA permitted p-tau217 in May 2025 for symptomatic patients, experts like Dr. Reisa Sperling advise asymptomatic individuals against testing until preventative therapies are approved.

P-tau217 blood test accuracy

▪A blood test measuring the phosphorylated tau 217 biomarker can predict the risk of developing cognitive impairment in healthy older adults years before symptoms appear.
▪The predictive accuracy of the p-tau217 biomarker operates independently of amyloid-beta plaques on PET scans and APOE4 genetic variations.

Five-year cognitive impairment risk

▪Cognitively healthy older adults with very high baseline levels of the p-tau217 biomarker face a 38% absolute risk of developing cognitive impairment within five years.
▪Study participants with very low baseline p-tau217 levels demonstrated a correspondingly low risk of developing cognitive impairment over a five-year period.

Ten-year cognitive impairment risk

▪Outside experts caution that the ten-year risk estimate is less certain than the five-year estimate because only a small fraction of study participants were tracked for a full decade.
▪The predictive risk of developing cognitive impairment for individuals with very high baseline p-tau217 levels escalates to 78% over a ten-year horizon.

Asymptomatic individual clinical limitations

▪The U.S. Food and Drug Administration began permitting the use of p-tau217 in May 2025, but only to help diagnose individuals aged 55 or older who are already showing early signs of cognitive decline.
▪Medical experts do not recommend p-tau217 blood tests for healthy, asymptomatic individuals in everyday clinical practice because there are no approved disease-modifying therapies for pre-clinical stages.

Prevention trial screening applications

▪Identifying high-risk individuals before symptoms manifest allows researchers to test preventive treatments when the brain is most receptive to preservation.
▪The primary immediate application for p-tau217 testing is the rapid, low-cost screening of high-risk, asymptomatic candidates for ongoing Alzheimer's disease prevention trials.

Multi-cohort study methodology

▪The study analyzed harmonized data from 2,684 cognitively unimpaired older adults pooled across six observational and clinical trial cohorts in North America, Japan, and Australia.
▪The longitudinal study tracked participants from enrollment starting as early as 2004 through follow-ups extending to 2025, during which 478 participants progressed to cognitive impairment.